Summary of Purpose
The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these...Read More →
The following dates are available for this trial. Trial information last updated on 24 April 2018.
|1 Jan 2017||14 Dec 2016||1 Jan 2020||1 Jan 2020||1 Apr 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
Conditions See All
- Jesse Corry Lead